| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 165.58 | 0.6% | 1.5% |
| Total Income | 165.94 | 0.7% | 1.5% |
| Expenditure | 161.36 | 10.5% | 7.6% |
| PBT | 4.59 | 69.8% | 66.3% |
| Net Profit | 3.24 | 85.1% | 76.0% |
| OPM | 9.81% | 6.14pp | 5.17pp |
| NPM | 1.95% | 11.22pp | 6.30pp |
| EPS | 0.93 | 87.3% | 77.4% |
Pharma: revenue nearly flat (+1.5% YoY) while OPM compressed ~510bps (14.98%→9.81%) and adjusted PAT fell 76% YoY, a clear below-par quarter driven by cost pressure rather than core growth.
Wanbury Ltd Secures EDQM Approval for Rivaroxaban API, USFDA DMF Clearances
13 Aug 2026 · 13 Aug, 12:48 pm
Summary
W anbury Limited has announced significant regulatory milestones. The company received approval from the European Directorate for the Quality of Medicines and Healthcare (EDQM) for its new Rivaroxaban API product. Furthermore, W anbury Limited secured DMF clearances from the USFDA for both Paraxetine HCI and Metformin HCI. These approvals are anticipated to enhance the company's ability to serve customer demand in the EU and other international markets, while the ANDA reviews indicate further growth potential.
Key Highlights
- 1
W anbury Limited received approval from the EDQM for the new product Rivaroxaban API, enabling expansion into EU and other CEP-accepting countries.
- 2
The company secured DMF clearance from the USFDA for Paraxetine HCI.
- 3
USFDA DMF clearance was also obtained for Metformin HCI.
- 4
W anbury Limited is undergoing ANDA review for multiple customers.
- 5
The approvals are expected to help meet growing customer demand in key international markets.
Informational and educational content only. Not investment advice.